Notably, the fusion in receptor tyrosine kinase c-ros oncogene 1 (ROS1) and ret proto-oncogene (RET) genes offer a distinct molecular classification of NSCLC patients and show a high potential to be candidate targets [18–24]. Here, ROS1 is linked to non-small cell lung carcinoma.